The Peripheral T-Cell Lymphomas. Группа авторов
progression of PTCL.
Table 4.1 Mouse models of peripheral T‐cell lymphomas (PTCL)
| Types of PTCL | Models | Methods | Phenotypes of mice | Others (downstream signaling, etc.) | Reference |
|---|---|---|---|---|---|
| AITL | Roquinsan | Heterozygous for Roquinsan : a missense (M199R) sanroque mutation in the Roquin gene | Increase of TFH cells AITL‐like disease around 4 to 15 months | No ROQUIN gene alterations in human AITL | Ellyard4 |
| Tet2 gene trap | A gene‐trap vector inserted into the Tet2 second intron | Development of T‐cell lymphomas with TFH‐like phenotype around 67 weeks | Hypermethylation of silencer region of Bcl6 gene | Muto10 | |
| G17V RHOA | G17V RHOA cKI mice crossed with CD4Cre‐ERT2 | Increase of TFH cells | Cortes14 | ||
| G17V RHOA transgenic mice under the Cd4 promoter | Increase of TFH cells Autoimmunity | Ng15 | |||
| G17V RHOA transgenic mice under the CD2 promoter | No phenotype | Nguyen16 | |||
| G17V RHOA‐Tet2 null | Retroviral transduction of G17V RHOA mutant cDNA into Tet2‐null T cells | Increase of TFH cells CD4+ proliferation | Inactivation of FoxO1 | Zang13 | |
| G17V RHOA cKI mice crossed with CD4CreERT2 and Tet2cKO with SRBC immunization | AITL‐like disease around 25 weeks | ICOSL‐ICOS signaling Activation of PI3K‐mTOR signaling | Cortes14 | ||
| G17V RHOA transgenic mice crossed with Tet2cKO x Vav‐Cre, and OT‐II mice with NP‐40‐Ovalbumin immunization | AITL‐like disease around 38 weeks | Activation of PI3K‐mTOR signaling | Ng15 | ||
| G17V RHOA transgenic mice crossed with Tet2cKO x Mx1‐Cre mice | AITL‐like disease around 48 weeks | Activation of T‐cell receptor signaling | Nguyen16 | ||
| PDX | Inoculation of cells from lymph nodes of AITL patients into NOD/Shi‐scid, IL2Rgammanull (NOG) mice | AITL‐like disease | Detection of human immunoglobulin G/A/M in the sera | Sato18 | |
| ALCL | NPM1‐ALK | Retroviral transduction of NPM1‐ALK cDNA into 5‐ fluorouracil‐treated murine BM | B‐lineage large cell lymphomas around 4‐6 months | Kuefer20 | |
| Retroviral transduction of NPM1‐ALK cDNA with low versus high multiplicity of infection (MOI) | Plasmacytomas around 12‐16 weeks with lower MOI, Histiocytic malignancies around 3‐4 weeks with higher MOI | Miething21 | |||
| Retroviral transduction of Lox‐STOP‐Lox‐NPM1‐ALK encoding vector in BM expressing Cre under the LyzM-promotor or GrzmB‐promotor | Histiocytic malignancies around 4‐6 weeks for LyzM, Mixed phenotype of T‐cell lymphoma/ histiocytic malignancy around 4‐6 weeks for GrzmB | Miething22 | |||
| NPM1‐ALK transgenic mice under the Cd4 promoter | Thymic lymphomas and plasmacytomas around 18 weeks | Activation of Stat3 signaling | Chiarle23,24 | ||
| NPM1‐ALK transgenic mice under the Vav1 promoter | Diffuse large B‐cell lymphomas with high copy number Plasmacytomas with low copy number | Turner25 | |||
| NPM1‐ALK transgenic mice under the Cd2 promoter | B‐cell lymphomas with variable histological features | Turner26 | |||
| CRISPR‐based models to make Npm1‐Alk in HSC | ALCL, ALK+‐like disease | Rajan27 | |||
| PDX | Cells from a patient with systemic CD30+ ALCL resistant to chemotherapy were inoculated into SCID mice | ALCL, ALK+‐like disease | Pfeifer28 | ||
| ATL CTCL | TAX HBZ | Tax transgenic mice under the control of viral promoters, HTLV‐1 LTR | Mesenchymal tumors, arthritis, and osteoporosis | Nerenberg30, Habu31, and Ruddle32 | |
| Tax transgenic mice under the Cd3‐epsilon promoter | Mesenchymal tumors, and salivary and mammary adenomas | Hall33 | |||
| Tax transgenic mice under the Lck proximal promoter | Thymic T‐cell lymphomas | Hasegawa34 | |||
| Tax transgenic mice under the GrzmB promoter | LGL and hypercalcemia | Grossman35 Gao36 | |||
| HBZ transgenic mice under the Cd4 promoter |
Increase of effector/memory and regulatory CD4+ T cells Inflammation of |